COVID-19 Impact on Thermo Fisher Scientific Inc.’s Revenue and Operations (Medical Devices)


Summary

Thermo Fisher Scientific Inc. (Thermo Fisher) is a provider of reagents, consumables, services, software, and scientific instrumentation, headquartered in the US with global manufacturing and sales reach. Thermo Fisher provides a wide range of solutions related to Pharma & Biotech, Diagnostics & Healthcare, Industrial & Applied, and Academia & Government. The report, COVID-19 Impact on Thermo Fisher Scientific Inc.’s Revenue and Operations (Medical Devices) presents a deep dive analysis into how Thermo Fisher Scientific Inc. is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.

Deep dive analysis into how Thermo Fisher Scientific Inc. is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.


Key Highlights

  • Thermo Fisher had a strong momentum before the outbreak of COVID-19 in China, followed by North America and Europe in March.
  • Thermo Fisher reported organic growth of 2% in Q1 2020 compared to Q1 2019.
  • However, the business was down approximately 25% in China to due to the outbreak of COVID-19.
  • On March 3rd 2020 the company announced its acquisition of Qiagen N.V., which will bode well for the company due to Qiagen’s FDA approved and CE marked COVID-19 test kits.




Scope

The report provides a comprehensive analysis of the impact of COVID-19 on Thermo Fisher Scientific Inc. -

  • It provides insights on Thermo Fisher Scientific Inc.’s exposure to the regions and businesses impacted by the COVID-19 outbreak.
  • It offers an overview of the company’s revenue impact by region and market for 2020 due to the COVID-19 outbreak.




Reasons To Buy

  • An overview of how Thermo Fisher Scientific Inc. will be affected by the COVID-19 pandemic.